Global Liver Cancer Therapeutics Market - 2023-2033

September 2025 | 200 pages | ID: GFA709963239EN
DataM Intelligence

Abstracts

The Global Liver Cancer Therapeutics Market was valued at US$ 2.92billion in 2023 and is anticipated to reach US$ 13.16billion by 2033, at a CAGR of 0.165 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Global Liver Cancer Therapeutics Market.
This report delivers a comprehensive overview of the Global Liver Cancer Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Liver Cancer Therapeutics Market. The Global Liver Cancer Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–2033.
Global Liver Cancer Therapeutics Market Scope:
Key Players

• AstraZeneca
• Bayer AG
• Eli Lilly
• Bristol-Myers Squibb Company
• Eisai Co., Ltd.
• Genentech

Major Highlights
This report delivers a comprehensive overview of the Global Liver Cancer Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Liver Cancer Therapeutics Market. The Global Liver Cancer Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–2033.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

• Increase Your Customer Base by 3X using our Partner Identification tool
• Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
• Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
• Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Contents

1. MARKET INTRODUCTION AND SCOPE

1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Type
2.4. Snippet by Therapy
2.5. Snippet by Route of Administration
2.6. Snippet by Distribution Channel
2.7. Snippet by Region

3. DYNAMICS

3.1. Impacting Factors
  3.1.1. Drivers
    3.1.1.1. Rising Incidence of Liver Cancer
    3.1.1.2. Advancements in Targeted Therapies and Immunotherapies
  3.1.2. Restraints
    3.1.2.1. High Cost of Liver Cancer Treatment
    3.1.2.2. Limited Awareness and Late Diagnosis in Developing Regions
  3.1.3. Opportunity
    3.1.3.1. Development of Combination Therapies and Precision Medicine
    3.1.3.2. Increased R&D Investment and Pipeline Expansion by Key Players
  3.1.4. Impact Analysis

4. LIVER CANCER THERAPEUTICS MARKET: STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

4.1. Market Leaders and Pioneers
  4.1.1. Emerging Pioneers and Prominent Players
  4.1.2. Established leaders with largest largest-selling Brand
  4.1.3. Market leaders with established products& Services
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
  4.3.1. North America
  4.3.2. Europe
  4.3.3. Asia Pacific
  4.3.4. South America
  4.3.5. Middle East & Africa
4.4. Porter’s Five Force Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
4.10. Pricing Analysis and Price Dynamics

5. LIVER CANCER THERAPEUTICS MARKET: BY TYPE

5.1. Introduction
  5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  5.1.2. Market Attractiveness Index, By Type
5.2. Hepatocellular Carcinoma*
  5.2.1. Introduction
  5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Cholangio Carcinoma
5.4. Hepatoblastoma
5.5. Others

6. LIVER CANCER THERAPEUTICS MARKET: BY THERAPY

6.1. Introduction
  6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
  6.1.2. Market Attractiveness Index, By Therapy
6.2. Chemotherapy*
  6.2.1. Introduction
  6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  6.2.3. Gemcitabine
  6.2.4. Oxaliplatin
  6.2.5. Cisplatin
  6.2.6. Others
6.3. Immunotherapy
  6.3.1. PD-1 and PD-L1 inhibitors
  6.3.2. CTLA-4 inhibitors
6.4. Targeted Therapy
  6.4.1. Atezolizumab (Tecentriq)
  6.4.2. Atezolizumab and hyaluronidase-tqjs
  6.4.3. Bevacizumab (Avastin)
  6.4.4. Cabozantinib-s-malate (Cabometyx)
6.5. Others

7. LIVER CANCER THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Oral*
  7.2.1. Introduction
  7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Intravenous

8. LIVER CANCER THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Hospital Pharmacies*
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacies
8.4. Online Pharmacies

9. LIVER CANCER THERAPEUTICS MARKET REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES

9.1. Introduction
  9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  9.1.2. Market Attractiveness Index, By Region
9.2. North America
  9.2.1. Introduction
  9.2.2. Key Region-Specific Dynamics
  9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
  9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), ByDistribution Channel
  9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    9.2.7.1. U.S.
    9.2.7.2. Canada
    9.2.7.3. Mexico
9.3. Europe
  9.3.1. Introduction
  9.3.2. Key Region-Specific Dynamics
  9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
  9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    9.3.7.1. Germany
    9.3.7.2. U.K.
    9.3.7.3. France
    9.3.7.4. Spain
    9.3.7.5. Italy
    9.3.7.6. Rest of Europe
9.4. South America
  9.4.1. Introduction
  9.4.2. Key Region-Specific Dynamics
  9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
  9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    9.4.7.1. Brazil
    9.4.7.2. Argentina
    9.4.7.3. Rest of South America
9.5. Asia-Pacific
  9.5.1. Introduction
  9.5.2. Key Region-Specific Dynamics
  9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
  9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    9.5.7.1. China
    9.5.7.2. India
    9.5.7.3. Japan
    9.5.7.4. South Korea
    9.5.7.5. Rest of Asia-Pacific
9.6. Middle East and Africa
  9.6.1. Introduction
  9.6.2. Key Region-Specific Dynamics
  9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
  9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

10.1. Competitive Overview and Key Market Players
10.2. Market Share Analysis and Positioning Matrix
10.3. Strategic Partnerships, Mergers & Acquisitions
10.4. Key Developments in Product Portfolios and Innovations
10.5. Company Benchmarking

11. COMPANY PROFILES

11.1. AstraZeneca*
  11.1.1. Company Overview
  11.1.2. Product Portfolio
    11.1.2.1. Product Description
    11.1.2.2. Product Key Performance Indicators (KPIs)
    11.1.2.3. Historic and Forecasted Product Sales
    11.1.2.4. Product Sales Volume
  11.1.3. Financial Overview
    11.1.3.1. Company Revenue
    11.1.3.2. Geographical Revenue Shares
    11.1.3.3. Revenue Forecasts
  11.1.4. Key Developments
    11.1.4.1. Mergers & Acquisitions
    11.1.4.2. Key Product Development Activities
    11.1.4.3. Regulatory Approvals, etc.
  11.1.5. SWOT Analysis
11.2. Bayer AG
11.3. Eli Lilly
11.4. Bristol-Myers Squibb Company
11.5. Eisai Co., Ltd.
11.6. Genentech (LIST NOT EXHAUSTIVE )

12. ASSUMPTIONS AND RESEARCH METHODOLOGY

12.1. Data Collection Methods
12.2. Data Triangulation
12.3. Forecasting Techniques
12.4. Data Verification and Validation

13. APPENDIX

13.1. About Us and Services
13.2. Contact Us